介导肿瘤细胞G2期周期阻滞的分子机制

摘要/Abstract

摘要：肿瘤的形成与进展离不开肿瘤细胞中细胞周期调控蛋白的改变，利用肿瘤细胞的G2M期周期阻滞效应在减缓肿瘤的生长、提高治疗疗效方面尤为重要。DNA损伤的感受器、信号传导因子和效应器是介导肿瘤细胞G2期周期阻滞的经典途径，且有作为新型肿瘤治疗靶点的可能。

林琳,周菊英. 介导肿瘤细胞G2期周期阻滞的分子机制[J]. 国际肿瘤学杂志, 2017, 44(3): 186-189.

Lin Lin, Zhou Juying. Molecular mechanism of G2 phase cell cycle arrest in tumor cellsLin Lin*, Zhou Juying. *Department of Radiation Oncology, First Affiliated Hospital of Soochow University, Suzhou 215000, China[J]. Journal of International Oncology, 2017, 44(3): 186-189.

参考文献

［1］ Meng X, Laidler LL, Kosmacek EA, et al. Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with nonfunctional p53［J］. Gynecol Oncol, 2013, 128(3): 461-469. DOI: 10.1016/j.ygyno.2012.11.004. ［2］ Larsen DH, Stucki M. Nucleolar responses to DNA doublestrand breaks ［J］. Nucleic Acids Res, 2016, 44(2): 538544. DOI: 10.1093/nar/gkv1312. ［3］ De Cicco M, Rahim MS, Dames SA. Regulation of the target of rapamycin and other phosphatidylinositol 3kinaserelated kinases by membrane targeting［J］. Membranes, 2015, 5(4): 553-575. DOI: 10.3390/membranes5040553. ［4］ Malaquin N, CarrierLeclerc A, Dessureault M, et al. DDRmediated crosstalk between DNAdamaged cells and their microenvironment［J］. Front Genet, 2015, 6: 94. DOI: 10.3389/fgene.2015.00094. ［5］ Siddiqui MS, Franois M, Fenech MF, et al. Persistent γH2AX: a promising molecular marker of DNA damage and aging［J］. Mutat Res Rev Mutat Res, 2015, 766: 1-19. DOI: 10.1016/j.mrrev.2015.07.001. ［6］ Monsalve DM, CampilloMarcos I, Salzano M, et al. VRK1 phosphorylates and protects NBS1 from ubiquitination and proteasomal degradation in response to DNA damage［J］. Biochim Biophys Acta, 2016, 1863(4): 760-769. DOI: 10.1016/j.bbamcr.2016.02.005. ［7］ Khongkow P, Karunarathna U, Khongkow M, et al. FOXM1 targets NBS1 to regulate DNA damageinduced senescence and epirubicin resistance［J］. Oncogene, 2014, 33(32): 4144-4155. DOI: 10.1038/onc.2013.457. ［8］ Park S, Kang JM, Kim SJ, et al. Smad7 enhances ATM activity by facilitating the interaction between ATM and Mre11Rad50Nbs1 complex in DNA doublestrand break repair［J］. Cell Mol Life Sci, 2015, 72(3): 583- 596. DOI: 10.1007/s000180141687z. ［9］ Liu XY, Zha S. ATMIN: a new tumor suppressor in developing B cells［J ］. Cancer Cell, 2011, 19(5): 569-570. DOI: 10.1016/j.ccr.2011.05.002. ［10］ Loizou JI, Sancho R, Kanu N, et al. ATMIN is required for maintenance of genomic stability and suppression of B cell lymphoma［J］. Cancer Cell, 2011, 19(5): 587-600. DOI: 10.1016/j.ccr.2011.03.022. ［11］ Rizzo A, Salvati E, Porru M, et al. Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATRdependent ATM signaling pathway［J］. Nucleic Acids Res, 2009, 37(16): 5353-5364. DOI: 10.1093/nar/gkp582. ［12］ Spagnolo L, Barbeau J, Curtin NJ, et al. Visualization of a DNAPK/PARP1 complex［J］. Nucleic Acids Res, 2012, 40(9): 4168-4177. DOI: 10.1093/nar/gkr1231. ［13］ VidalEychenie S, Decaillet C, Basbous JA. DNA structurespecific priming of ATR activation by DNAPK［J］. J Cell Biol, 2013, 202(3): 421- 429. DOI: 10.1083/jcb.201304139. ［14］ Xue L, Yu D, Furusawa Y, et al. ATMdependent hyperradiosensitivity in mammalian cells irradiated by heavy ions［J］. Int J Radiat Oncol Biol Phys, 2009, 75(1): 235-243. DOI: 10.1016/j.ijrobp.2009.04.088. ［15］ Cui YX, Palii SS, Innes CL, et al. Depletion of ATR selectively sensitizes ATMdeficient human mammary epithelial cells to ionizing radiation and DNAdamaging agents［J］. Cell Cycle, 2014, 13(22): 3541-3550. DOI: 10.4161/15384101.2014.960729. ［16］ Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer［J］ . Pharmacol Ther, 2015, 149: 124-138. DOI: 10.1016/j.pharmthera.2014.12.001. ［17］ Wang XQ, Redpath JL, Fan ST, et al. ATR dependent activation of Chk2 ［J］. J Cell Physiol, 2006, 208(3): 613-619. DOI: 10.1002/jcp.20700. ［18］ Zhang J, Gao G, Chen L, et al. Hydrogen peroxide/ATRChk2 activation mediates p53 protein stabilization and anticancer activity of cheliensisin a in human cancer cells［J］. Oncotarget, 2014, 5(3): 841-852. ［19］ Niida H, Murata K, Shimada M, et al. Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo［J］. EMBO J, 2010, 29(20): 3558-3570. DOI: 10.1038/emboj.2010.218. ［20］ Manic G, Obrist F, Sistigu A, et al. Trial watch: targeting ATMCHK2 and ATRCHK1 pathways for anticancer therapy［J］. Mol Cell Oncol, 2015, 2(4): e1012976. DOI: 10.1080/23723556.2015.1012976. ［21］ Lavecchia A, Di Giovanni C, Novellino E. CDC25 phosphatase inhibitors: an update［J］. Mini Rev Med Chem, 2012, 12(1): 62-73. ［22］ Wu YJ, Jan YJ, Ko BS, et al. Involvement of 1433 proteins in regulating tumor progression of hepatocellular carcinoma［J］. Cancers (Basel), 2015, 7(2): 1022-1036. DOI: 10.3390/cancers7020822. ［23］ Agius E, BelVialar S, Bonnet F, et al. Cell cycle and cell fate in the developing nervous system: the role of CDC25B phosphatase［J］. Cell Tissue Res, 2015, 359(1): 201-213. DOI: 10.1007/s0044101419982. ［24］ Vriend LE, De Witt Hamer PC, Van Noorden CJ, et al. WEE1 inhibition and genomic instability in cancer［J］. Biochim Biophys Acta, 2013, 1836 (2): 227-235. DOI: 10.1016/j.bbcan.2013.05.002. ［25］ Li S, Zhang Y, Xu W. Developments of pololike kinase 1 (Plk1) inhibitors as anticancer agents［J］. Mini Rev Med Chem, 2013, 13(14): 2014-2025. ［26］ Wang LM, Lv WW, Zuo D, et al. Characteristics of cyclin B and its potential role in regulating oogenesis in the red claw crayfish (cherax quadricarinatus)［J］. Genet Mol Res, 2015, 14(3): 10786-10798. DOI: 10.4238/2015.September.9.17.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.